Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
- 18 years of age or over.
- At least one suspected soft tissue sarcoma tumor that is considered by the investigator to be: (1) accessible for percutaneous injection and (2) at least 2.5 cm in shortest dimension for patients undergoing an incisional biopsy, or at least 3 cm in shortest dimension for patients undergoing an excisional biopsy/tumor resection. Tumors should not be selected if the Investigator believes them to be necrotic or exhibit signs of radiation-induced fibrosis.
- Prior surgical evaluation and plan for surgical biopsy or surgery to remove the tumor being injected.
- ECOG performance status of 0-2 (or a Karnofsky performance status of >50%)
- Labs required for enrollment (prior to microinjection):
- Absolute neutrophil count > 1000/mm3
- Platelet count > 50,000/mm3
- Hematocrit > 25%
- Creatinine <3.0 mg/dl
- Total Bilirubin <4.0 mg/dl
- Bilirubin <4.0 mg/dl, SGOT ≤ 1.5 times the upper limit of normal
- PT and PTT ≤ 1.5 times the upper limit of normal
- Subjects with active fungal, viral, or bacterial infections.
- Pregnant women.
- Inability to give informed consent.
- Current treatment with anticoagulation such as warfarin or low-molecular-weight heparin.
- Tumors near critical structures such as those located near or in the brain or spine. This assessment will be determined by the treating clinician.
This is a single arm, pilot study designed to test the feasibility of using the CIVO
(Comparative In Vivo Oncology) system in patients with soft tissue sarcoma accessible for
percutaneous injection. Patients who are scheduled for surgical biopsy or tumor resection
surgery will be injected 4 to 72 hours prior to surgery using the CIVO device. Minute volumes
(up to 8.3 microliters) of saline (negative control) or microdoses of anti-cancer agents will
be percutaneously injected in a columnar fashion through each of 8 needles into a single
solid tumor. Following the patient's biopsy surgery or tumor resection surgery, the injected
portion and a small uninjected portion will be used to determine the in situ drug response in
the tumor. None of the data from this evaluation will be shared with patients or used to make
clinical decisions. Study clinicians will have access to the patient's health record for 1
year after the study to monitor patient treatment responses. Such information will be used to
help evaluate the correlation between clinical response and tumor response assessed via CIVO.
Trial Phase Phase I
Trial Type Basic science
- Primary ID PRS-2
- Secondary IDs NCI-2017-00513
- Clinicaltrials.gov ID NCT03056599